Sakar Healthcare Past Earnings Performance
Past criteria checks 2/6
Sakar Healthcare has been growing earnings at an average annual rate of 12.5%, while the Pharmaceuticals industry saw earnings growing at 14.2% annually. Revenues have been growing at an average rate of 15.8% per year. Sakar Healthcare's return on equity is 5.3%, and it has net margins of 8.2%.
Key information
12.5%
Earnings growth rate
5.1%
EPS growth rate
Pharmaceuticals Industry Growth | 17.5% |
Revenue growth rate | 15.8% |
Return on equity | 5.3% |
Net Margin | 8.2% |
Last Earnings Update | 31 Dec 2023 |
Recent past performance updates
Recent updates
Is Sakar Healthcare (NSE:SAKAR) A Risky Investment?
Dec 28Does Sakar Healthcare (NSE:SAKAR) Have A Healthy Balance Sheet?
Aug 05Is Sakar Healthcare (NSE:SAKAR) A Risky Investment?
Mar 29Here's Why Sakar Healthcare (NSE:SAKAR) Has Caught The Eye Of Investors
Jan 31Is Sakar Healthcare (NSE:SAKAR) Using Too Much Debt?
Dec 01Sakar Healthcare (NSE:SAKAR) Has A Somewhat Strained Balance Sheet
Jul 13Sakar Healthcare (NSE:SAKAR) Has A Somewhat Strained Balance Sheet
Mar 26With EPS Growth And More, Sakar Healthcare (NSE:SAKAR) Is Interesting
Jul 01Here's Why I Think Sakar Healthcare (NSE:SAKAR) Might Deserve Your Attention Today
Mar 23Insider Buying: The Sakar Healthcare Limited (NSE:SAKAR) Chairman & MD Just Bought 7.1% More Shares
Mar 02Has Sakar Healthcare Limited's (NSE:SAKAR) Impressive Stock Performance Got Anything to Do With Its Fundamentals?
Feb 08Does Sakar Healthcare (NSE:SAKAR) Have A Healthy Balance Sheet?
Jan 10Here's Why I Think Sakar Healthcare (NSE:SAKAR) Is An Interesting Stock
Dec 14Should You Rely On Sakar Healthcare's (NSE:SAKAR) Earnings Growth?
Nov 22Revenue & Expenses BreakdownBeta
How Sakar Healthcare makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
---|---|---|---|---|
31 Dec 23 | 1,518 | 125 | 201 | 0 |
30 Sep 23 | 1,480 | 144 | 203 | 0 |
30 Jun 23 | 1,438 | 127 | 189 | 0 |
31 Mar 23 | 1,342 | 128 | 169 | 0 |
31 Dec 22 | 1,302 | 178 | 169 | 0 |
30 Sep 22 | 1,265 | 139 | 155 | 0 |
30 Jun 22 | 1,265 | 144 | 152 | 0 |
31 Mar 22 | 1,291 | 152 | 154 | 0 |
31 Dec 21 | 1,139 | 80 | 131 | 0 |
30 Sep 21 | 1,109 | 97 | 133 | 0 |
30 Jun 21 | 1,054 | 118 | 134 | 0 |
31 Mar 21 | 953 | 107 | 133 | 0 |
31 Dec 20 | 913 | 118 | 137 | 0 |
30 Sep 20 | 870 | 122 | 132 | 0 |
30 Jun 20 | 884 | 106 | 130 | 0 |
31 Mar 20 | 839 | 96 | 123 | 0 |
31 Dec 19 | 851 | 88 | 114 | 0 |
30 Sep 19 | 844 | 86 | 112 | 0 |
30 Jun 19 | 744 | 78 | 98 | 0 |
31 Mar 19 | 688 | 67 | 91 | 0 |
31 Mar 18 | 534 | 38 | 69 | 0 |
31 Mar 17 | 447 | 34 | 60 | 0 |
31 Mar 16 | 414 | 22 | 50 | 0 |
31 Dec 15 | 386 | 24 | 49 | 0 |
31 Mar 15 | 350 | 18 | 40 | 0 |
31 Mar 14 | 297 | 18 | 33 | 0 |
Quality Earnings: SAKAR has high quality earnings.
Growing Profit Margin: SAKAR's current net profit margins (8.2%) are lower than last year (13.7%).
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: SAKAR's earnings have grown by 12.5% per year over the past 5 years.
Accelerating Growth: SAKAR's has had negative earnings growth over the past year, so it can't be compared to its 5-year average.
Earnings vs Industry: SAKAR had negative earnings growth (-29.9%) over the past year, making it difficult to compare to the Pharmaceuticals industry average (23.1%).
Return on Equity
High ROE: SAKAR's Return on Equity (5.3%) is considered low.